152.00
-2.23%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cochlear
Its shares trade on ASX under the ticker COH.AX. It has been listed since 4 December 1995. In the fiscal year to 30 June 2026, it reported revenue of A$2.33bn and net income of A$147.3m. At that date it held total assets of A$2.60bn and shareholders' equity of A$1.74bn.
Cochlear Ltd. engages in the provision of implantable hearing solutions. The company is headquartered in Sydney, New South Wales. The firm provides bone conduction implants for people with conductive hearing loss, mixed hearing loss and single-sided deafness. Its segments include Americas, EMEA and Asia Pacific. Americas includes the United States, Canada and Latin America. EMEA includes Europe, Middle East and Africa. Asia Pacific includes Australasia and Asia. Its implantable hearing solution portfolio includes Cochlear implants, such as Cochlear Nucleus Profile Plus with Slim Modiolar Electrode (CI632), Cochlear Nucleus Kanso Sound Processor (CP950), Cochlear Nucleus 7 Sound Processor (CP1000) and Cochlear Nucleus smart application and bone conduction implants, such as Cochlear Baha 5, Baha 5 Power and Baha 5 SuperPower, Cochlear Baha SoundArc, Cochlear Baha Smart App and Cochlear Carina System.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Dec 1995
- Employees
- 4,000
- Website
- cochlear.com ↗
Leadership
Pay as last reported
- Ms. Alison DeansNon-Executive Independent Chairman of the BoardA$596,779
- Mr. Diggory HowittPresident, Chief Executive Officer, Executive DirectorA$5.1m
- Ms. Sarah ThomChief Financial Officer
- Ms. Lisa AubertPresident - North AmericaA$384,079
- Mr. Anthony BishopPresident - EMEAA$1.4m
- Mr. Stuart SayersPresident, Asia Pacific & Latin AmericaA$1.8m
- Mr. Dean PhizackleaSenior Vice President - Global Strategic Marketing
- Mr. Greg BodkinSenior Vice President - Supply Chain & Operational Excellence
- Ms. Jennifer HornerySenior Vice President - People and Culture
- Mr. Brian KaplanSenior Vice President - Clinical Strategy and Innovation
- Mr. Jan JanssenChief Technology OfficerA$2.2m
- Ms. Karen O'driscollChief Information Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 64
- Social
- 99
- Governance
- 53
- Direct emissions (scope 1)
- 856 t
- Energy emissions (scope 2)
- 2,183 t
- Value chain emissions (scope 3)
- 14,418 t
- Women in the workforce
- 51%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cochlear Ltd possesses several key strengths that contribute to its success in the market. Firstly, the company is a pioneer and leader in the field of implantable hearing solutions, with over 30 years of experience. This enables them to offer innovative and technologically advanced products that provide significant benefits to individuals with hearing loss.
- Moreover, Cochlear has established a strong global presence with a wide distribution network spanning across more than 100 countries. This allows them to reach a large customer base and maintain strong relationships with healthcare professionals, ensuring accessibility and support for their products. Additionally, the company has a robust intellectual property portfolio, providing them with a competitive advantage in the market.
Weaknesses
- Despite its strengths, Cochlear Ltd faces a few weaknesses that could pose challenges. One significant weakness is the high cost associated with their implantable hearing solutions. This can limit their accessibility to a substantial portion of the population, particularly in developing countries or regions where healthcare budgets are constrained.
- Another weakness lies in the complexity of the surgical procedure required for implanting their hearing devices. This could deter potential customers who might prefer less invasive options or who are reluctant to undergo surgery. Additionally, as a specialized medical device company, Cochlear relies heavily on regulatory approvals, which can lead to delays in product launches and market entry.
Opportunities
- Cochlear Ltd operates in an industry with several significant opportunities. Firstly, the growing global prevalence of hearing loss, coupled with an aging population, presents a substantial market opportunity for the company. They can leverage their expertise and portfolio to address the unmet needs of individuals with hearing impairment worldwide.
- Furthermore, advancements in technology and digital healthcare offer opportunities for Cochlear to develop innovative solutions that improve user experience and convenience. The increasing adoption of telehealth and remote patient monitoring also opens new avenues for Cochlear to provide virtual support and services to its customers, enhancing accessibility and convenience.
Threats
- Cochlear Ltd operates in a competitive market with several threats that could impact its business. One significant threat is the presence of well-established competitors in the hearing solutions industry who have the financial resources and R&D capabilities to develop competitive products. This intensifies the need for Cochlear to maintain its focus on innovation and differentiation.
- Additionally, changes in healthcare policies and reimbursement systems can pose a threat to Cochlear's financial performance. Reimbursement cuts or changes in coverage policies may affect the affordability and accessibility of the company's products, impacting market demand. Lastly, economic downturns or financial crises can also have an adverse effect on Cochlear's business, as discretionary healthcare spending may decline during such periods.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.